Pharma

Your Article Summary

See Latest Articles

Two-Year SYNTAX Data Show Comparable Safety Outcomes for Complex Patients Treated With TAXUS EXPRESS Stents and Bypass Surger
Boston Scientific, 09/03/09

Boston Scientific Corporation announced two–year data from its SYNTAX clinical trial comparing percutaneous coronary intervention using the TAXUS Express Paclitaxel–Eluting Coronary Stent System to coronary artery bypass graft surgery. The overall results demonstrated no statistically significant difference between PCI and CABG in the composite safety endpoint. The Company made the announcement at the annual European Society of Cardiology (ESC) Congress in Barcelona.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Autologous blood therapy for common cold—A randomized, double-blind, placebo-controlled trial
Complementary Therapies in Medicine, 12/08/09

Efficacy and Safety of Efalizumab in Patients with Moderate-to-Severe Plaque Psoriasis Resistant to Previous Anti-Psoriatic Treatment: Results of a Multicentre, Open-label, Phase IIIb/IV Trial
Archives of Drug Information, 12/08/09

Cytokinetics Presents Non-Clinical Data Relating To CK-2017357 At The 5th Cachexia Conference
Cytokinetics, 12/08/09

 See all of Drug Trials

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

Cerner Enters R&D Pact with University
HealthDataManagement, 12/08/09

Report: Acquisition Activity Down
HealthDataManagement, 12/08/09

Takeda to Continue Strategic Expansion with Operations in Brazil
Takeda Pharmaceuticals North America, 12/08/09

 See all of Research & Development